RAFARMA PHARMACEUTICALS, INC. Due to the changed geopolitical situation, the company was unable to complete the review of some of the assets that were set for audit consolidation, namely Kraspharma and Bebig. The Company will continue to provide its shareholders with regular unaudited financial statements of Kraspharma and Bebig. Once the geopolitical climate changes, the company intends to complete the audit of these two assets and add them to the consolidated audited accounts.
Meanwhile, the company is working on and acquiring several assets and projects located in
The company is currently working with its auditor and will submit standard GAAP audit reports that will include the acquired assets. Announcements will also be made in the near future describing newly acquired assets and projects in which the company is involved.
New acquisitions will not dilute the current assets of the company's shareholders.
The recapitalization of the company will be carried out through preferred shares. Our goal is to restructure the company to expand our products and manufacturing capabilities into global markets while maintaining the original scale of operations.
We are going to focus on medical research and development, both in terms of devices and drugs. In addition, we are interested in creating partnerships to continue to benefit from new product launches. We hope to use the resulting innovative products to create a global innovative company worth at least
After assessing market changes and ongoing research projects in recent years, the company's development directions until 2028 were formed. Its portfolio includes nuclear medicine, biotechnology products, SMART packaging, and biotechnology research and development.
Below is the company's strategy for 2023-2028:
1. Transfer of projects and experience to open markets. Instead of unsafe transactions with Russian assets, we transferred our experience to more stable markets. Production lines are moving to
2. Stopping the project in
3. Introduction of microspheres as medical devices in
4. Completion of verification. The company expects that, taking into account the forced changes in its structure, the audit will be completed by the end of first quarter of 2024;
5. Additional investments. The company's management invests its own funds in the implementation of new projects by increasing the company's attracted capital without increasing the number of voting shares;
6. We plan to further capitalize and increase the profitability of existing assets:
●Medical polymers;
●Pharmaceutical substances and antibodies;
●Photopolymers and holographic products;
●Consumables for muon spectrography;
●Emulsion and colloidal photographic materials;
●Ultra-pure materials based on aluminum A5H and A6H (99.9999%) for microelectronics;
●Packaging materials for pharmaceuticals.
Rafarma has the potential to become a major driver of the modern healthcare industry in areas where we can do it best. We provide nuclear, technology and pharmaceutical solutions to hundreds of thousands of patients around the world. Our products are trusted by healthcare professionals and institutions around the world. Through a diversified product portfolio and a wide range of research projects, we strive to disseminate our work and our core values.
We believe that our commitment to saving and preserving the quality of life of patients, as well as the experience of our team, is the right combination to overcome this technological milestone. We focus on the areas we know best: nuclear medicine, new pharmaceuticals, medical devices and cancer treatment technologies. Our credo: we must save lives that should not be lost thanks to modern technological advances; we must preserve a quality of life that can be freed from unnecessary restrictions and suffering; and we must push medical progress forward.
The press conference with with shareholders hold on
ABOUT
For more information, please visit https://www.noyarp.com
FORWARD-LOOKING STATEMENT:
Forward-Looking Statements: This press release contains “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934. Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may”, “will”, “to”, “plan”, “expect”, “believe”, “anticipate”, “intend”, “could”, “would”, “estimate,” or “continue”, or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risk, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Also, forward-looking statements represent our management’s beliefs and assumptions only as of the date hereof. Additional information regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in the Company's filings with OTC Markets. Except as required by law, we assume no obligation to update these forward-looking statements publicly or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.
CONTACTS:
RAFARMA PHARMACEUTICALS
babenko_press@rafapharm.com
(307) 429-2029
Source:
2023 GlobeNewswire, Inc., source
